CORDIS
EU research results

CORDIS

English EN
Vaccine Design and Immune Responses

Vaccine Design and Immune Responses

Objective

The successful development of new vaccines depends on the interaction of industrial expertise for vaccine design and engineering with academic understanding of the mechanisms of protection afforded by the immune responses they elicit. Close interaction between both sectors expedites vaccine development and, in the context of global health, this can translate to the saving of thousands of lives. The VADER (Vaccine Design and Immune Responses) EID programme, established between the Novartis Vaccines Institute for Global Health (NVGH) in Italy and University of Birmingham (UoB) in the UK, will train four talented clinical and non-clinical fellows at the interface between academia and industry. NVGH is a company with a mission to develop affordable and effective vaccines against infectious diseases of impoverished communities in the developing world. Its first vaccine, against Salmonella Typhi, is in clinical trails in South-East Asia, with vaccines against Salmonella Paratyphi, nontyphoidal Salmonella, meningococcus and Shigella in preclinical development. UoB is an international leader in investigating immune responses to bacteria, particularly Salmonellae, and in relating immunity to microbial antigens. The two institutions have forged strong links over the last year which form the framework of the VADER programme. The fellows will work on four related projects embedded within existing vaccine programmes at NVGH where they will work as part of a team of scientists. With vaccines in clinical trials, trainees will be able to explore immune responses in human vaccinees as well as animals. In their projects, they will be trained in vaccine design and immunology and learn how differences in vaccine engineering affect immune responses. By working on both industrial and academic sides of vaccine development they receive a research training in translational and transferable skills and learn how both sectors can synergise in vaccine development.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

THE UNIVERSITY OF BIRMINGHAM

Address

Edgbaston
B15 2tt Birmingham

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 086 366

Administrative Contact

Calman Maclennan (Prof.)

Participants (1)

Sort alphabetically

Sort by EU Contribution

Expand all

GSK VACCINES INSTITUTE FOR GLOBAL HEALTH SRL

Italy

EU Contribution

€ 88 000

Project information

Grant agreement ID: 316940

Status

Closed project

  • Start date

    1 October 2012

  • End date

    30 September 2016

Funded under:

FP7-PEOPLE

  • Overall budget:

    € 1 174 366

  • EU contribution

    € 1 174 366

Coordinated by:

THE UNIVERSITY OF BIRMINGHAM

United Kingdom